Compound class:
Synthetic organic
Comment: BRD3444 is the hit compound from a series of bicyclic azetidines with promising antimalarial activity against all lifecycle stages of the Plasmodium parasite [1]. Note that BRD3444 has complex stereoisomers (PubChem same connectivity and via the UniChem InChIKey backbone search in our summary table below).
The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Guide to Malaria Pharmacology Comments |
BRD3444 has promising activity against multiple lifecycle stages of the Plasmodium parasite [1]. Note that this paper also discloses BRD1095 and BRD7929, advanced analogues that are more soluble, retain in vitro potency and with the same mechanism of action as BRD3444. Potential Target/Mechanism Of Action: Correlation of purified cFRS IC50 values against parasite growth inhibition assays for a range of analogues, together with genetic evidence, indicate that PfcFRS is the relevant molecular target of this bicyclic azetidine series [1]. |